6533b7dafe1ef96bd126ec7e
RESEARCH PRODUCT
New developments in the management of hepatitis C virus infection: focus on boceprevir
Marina BerenguerF. Xavier López-labradorsubject
viral resistanceNS3business.industryvirusesRibavirinHepatitis C virusStandard treatmentprotease inhibitorsReviewmedicine.disease_causeVirologyVirusTelaprevirchemistry.chemical_compoundchemistryBoceprevirHCVantiviral therapyMedicineEffective treatmentbusinessmedicine.drugdescription
Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%-50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-08-01 | Biologics: Targets and Therapy |